Co-Diagnostics Gross Profit Growth & History (CODX)
Co-Diagnostics's gross profit was $400,112 for fiscal 2025.
View full Co-Diagnostics company overviewCo-Diagnostics annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $400,112 | −$2.5M | −86.28% |
| 2024 | 2024-12-31 | $2.9M | $288,947 | +11.00% |
| 2023 | 2023-12-31 | $2.6M | −$26.1M | −90.86% |
| 2022 | 2022-12-31 | $28.7M | −$57.6M | −66.71% |
| 2021 | 2021-12-31 | $86.3M | $28.3M | +48.91% |
| 2020 | 2020-12-31 | $58.0M | $57.9M | +56424.01% |
| 2019 | 2019-12-31 | $102,543 | $72,023 | +235.99% |
| 2018 | 2018-12-31 | $30,520 | $23,160 | +314.67% |
| 2017 | 2017-12-31 | $7,360 | — | — |
Co-Diagnostics quarterly gross profit
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $120,828 | −$9,976 | −7.63% |
| Q1 2026 | 2026-03-31 | −$47,814 | −$76,501 | — |
| Q4 2025 | 2025-12-31 | $121,526 | $227,269 | — |
| Q3 2025 | 2025-09-30 | $119,095 | −$224,643 | −65.35% |
| Q2 2025 | 2025-06-30 | $130,804 | −$2.3M | −94.65% |
| Q1 2025 | 2025-03-31 | $28,687 | −$204,662 | −87.71% |
| Q4 2024 | 2024-12-31 | −$105,743 | −$693,079 | — |
| Q3 2024 | 2024-09-30 | $343,738 | −$1.9M | −84.38% |
| Q2 2024 | 2024-06-30 | $2.4M | $2.7M | — |
| Q1 2024 | 2024-03-31 | $233,349 | $133,633 | +134.01% |
| Q4 2023 | 2023-12-31 | $587,336 | −$298,373 | −33.69% |
| Q3 2023 | 2023-09-30 | $2.2M | −$2.1M | −49.12% |
| Q2 2023 | 2023-06-30 | −$261,289 | −$4.4M | — |
| Q1 2023 | 2023-03-31 | $99,716 | −$19.3M | −99.49% |
| Q4 2022 | 2022-12-31 | $885,709 | −$17.0M | −95.06% |
| Q3 2022 | 2022-09-30 | $4.3M | −$22.5M | −83.85% |
| Q2 2022 | 2022-06-30 | $4.1M | −$20.7M | −83.47% |
| Q1 2022 | 2022-03-31 | $19.4M | $2.7M | +15.91% |
| Q4 2021 | 2021-12-31 | $17.9M | −$4.9M | −21.54% |
| Q3 2021 | 2021-09-30 | $26.8M | $10.8M | +67.46% |
| Q2 2021 | 2021-06-30 | $24.9M | $6.8M | +37.58% |
| Q1 2021 | 2021-03-31 | $16.8M | $15.7M | +1470.34% |
| Q4 2020 | 2020-12-31 | $22.8M | $22.8M | +40846.51% |
| Q3 2020 | 2020-09-30 | $16.0M | $16.0M | +75828.96% |
| Q2 2020 | 2020-06-30 | $18.1M | $18.0M | +79254.14% |
| Q1 2020 | 2020-03-31 | $1.1M | $1.1M | +36086.84% |
| Q4 2019 | 2019-12-31 | $55,761 | $54,329 | +3793.92% |
| Q3 2019 | 2019-09-30 | $21,069 | $11,373 | +117.30% |
| Q2 2019 | 2019-06-30 | $22,765 | $13,069 | +134.79% |
| Q1 2019 | 2019-03-31 | $2,948 | −$6,748 | −69.60% |
| Q4 2018 | 2018-12-31 | $1,432 | — | — |
| Q3 2018 | 2018-09-30 | $9,696 | $7,098 | +273.21% |
| Q2 2018 | 2018-06-30 | $9,696 | $7,532 | +348.06% |
| Q1 2018 | 2018-03-31 | $9,696 | — | — |
| Q3 2017 | 2017-09-30 | $2,598 | — | — |
| Q2 2017 | 2017-06-30 | $2,164 | — | — |
Co-Diagnostics gross profit trends
Over the last five fiscal years, Co-Diagnostics's gross profit decreased from $58.0M to $400,112, a change of −$57.6M. The latest reported quarter, Q2 2026, shows $120,828.
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Co-Diagnostics source filings ↗